Follow The Filings

XLO Xilio Therapeutics

Xilio Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by XLO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All XLO insider trades
  • $44K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. James Samuel Shannon Director
    Buy
    $44K 5,000 shares at $8.79 +100% to stake
    Traded Mar 26 Filed Mar 30
    ↗

Also filed in the last 12 months, not counted as buying or selling: 4 option exercises and 2 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 3.03,5.03,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
424B5 Filing Doc
DEF 14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.